Drug Search Results
More Filters [+]

VL#FIA3-30

Alternative Names: vl#fia3-30, vl#fia330, vl#fia3 30
Latest Update: 2015-07-15
Latest Update Note: Clinical Trial Update

Product Description

VL#FIA3-30 is a preparation intended for topical use, applied on the penis, for the treatment of ED. VasoLead's preparation to treat erectile dysfunction (ED), VL#FIA3-30, is composed of 2 active pharmaceutical ingredients, both act as vasodilators via different mechanisms. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02496845)

Mechanisms of Action: ADRA1 Antagonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Transdermal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: VasoLead (2012)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VL#FIA3-30

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Erectile Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

VL#FIA3-30 #002

P2

Unknown status

Erectile Dysfunction

2015-11-01

Recent News Events

Date

Type

Title